Hims & Hers Health (NYSE:HIMS) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Hims & Hers Health (NYSE:HIMS) from a hold rating to a strong sell rating in a report issued on Monday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Leerink Partnrs raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Finally, Barclays started coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $44.54.

Hims & Hers Health Trading Down 3.0%

Shares of HIMS stock opened at $30.44 on Monday. The firm has a fifty day moving average of $35.41 and a 200-day moving average of $45.43. The stock has a market cap of $6.93 billion, a price-to-earnings ratio of 56.37, a P/E/G ratio of 5.32 and a beta of 2.37. Hims & Hers Health has a 52-week low of $23.97 and a 52-week high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the firm posted $0.32 earnings per share. Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has approved a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 125,544 shares of company stock valued at $4,620,821. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock valued at $1,107,062,000 after purchasing an additional 844,991 shares in the last quarter. Capital World Investors raised its holdings in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares in the last quarter. State Street Corp lifted its stake in Hims & Hers Health by 1.9% in the third quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after buying an additional 132,384 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 1.5% in the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after buying an additional 71,593 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.